Back to Journals » Clinical Ophthalmology » Volume 7

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Authors Inoue K, Tanaka A, Tomita G, Fujimoto T

Received 6 April 2013

Accepted for publication 27 May 2013

Published 9 July 2013 Volume 2013:7 Pages 1411—1416

DOI https://doi.org/10.2147/OPTH.S46340

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Kenji Inoue,1 Ayumi Tanaka,1 Goji Tomita2

1Inouye Eye Hospital, 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan

Purpose: To evaluate the effects of tafluprost treatment for 3 years on intraocular pressure (IOP) and visual field performance.
Methods: The IOP of 55 patients with normal-tension glaucoma was monitored every 1–3 months for 3 years. The Humphrey visual field test was performed every 6 months after treatment and results compared with before-treatment results. Visual field performance was also evaluated by trend and event analysis.
Results: After 3 years’ tafluprost single-use vials treatment, the IOP (12.8 ± 2.8 mmHg [mean ± standard deviation]) was significantly lower than before treatment (15.7 ± 2.2 mmHg; P < 0.0001). When comparing before-treatment Humphrey visual field test findings with those after 3 years of treatment, no change was found in the mean deviation and pattern standard deviation. Visual field performance had worsened in four patients and three patients according to trend analysis and event analysis, respectively. Adverse reactions appeared in ten cases and one patient (1.8%) discontinued treatment due to an adverse reaction.
Conclusion: Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%–13.8% in patients with normal-tension glaucoma. Safety was satisfactory.

Keywords: intraocular pressure, visual field, trend analysis, event analysis


A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]